The cost-effectiveness of a pharmacogenetic test: a trial-based evaluation of TPMT genotyping for azathioprine.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Value in Health

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jval.2013.10.007PMID 24438714
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cost Effectiveness of Pharmacogenomics

  2012cited by this paper
• Pharmacoeconomic Analyses of Azathioprine, Methotrexate and Prospective Pharmacogenetic Testing for the Management of Inflammatory Bowel Disease

  2012cited by this paper
• Tails from the peak district: adjusted limited dependent variable mixture models of EQ-5D questionnaire health state utility values.

  2012cited by this paper
• Pharmacoeconomic Evaluations of Pharmacogenetic and Genomic Screening Programmes

  2012cited by this paper
• The NICE Cost-Effectiveness Threshold

  2012cited by this paper
• Multiple imputation using chained equations: Issues and guidance for practice

  2011cited by this paper
• British Association of Dermatologists’ guidelines for the safe and effective prescribing of azathioprine 2011

  2011cited by this paper
• A pragmatic randomized controlled trial of thiopurine methyltransferase genotyping prior to azathioprine treatment: the TARGET study.

  2011cited by this paper
• Guidelines for the management of inflammatory bowel disease in adults

  2011cited by this paper
• Valuing pharmacogenetic testing services: a comparison of patients' and health care professionals' preferences.

  2011cited by this paper
• Cost-effectiveness analysis in pharmacogenomics.

  2010cited by this paper
• Thiopurine S-methyltransferase (TPMT) assessment prior to starting thiopurine drug treatment; a pharmacogenomic test whose time has come

  2010influential reference
• Non-parametric methods for cost-effectiveness analysis: the central limit theorem and the bootstrap compared.

  2010cited by this paper
• TPMT testing in azathioprine: a 'cost-effective use of healthcare resources'?

  2009cited by this paper
• Addressing the Challenges of the Clinical Application of Pharmacogenetic Testing

  2009cited by this paper
• The validity and responsiveness of generic utility measures in rheumatoid arthritis: a review.

  2008cited by this paper
• BSR/BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists.

  2008cited by this paper
• Thiopurine dose in intermediate and normal metabolizers of thiopurine methyltransferase may differ three-fold.

  2008cited by this paper
• 'Drug reactions, enzymes, and biochemical genetics': 50 years later.

  2007cited by this paper
• Current use of pharmacogenetic testing: a national survey of thiopurine methyltransferase testing prior to azathioprine prescription

  2007cited by this paper
• Cost-effectiveness in clinical trials: using multiple imputation to deal with incomplete cost data

  2007cited by this paper
• Economic Evaluation in Clinical Trials

  2007cited by this paper
• Whither trial-based economic evaluation for health care decision making?

  2006cited by this paper
• Extended Generalized Linear Models: Simultaneous Estimation of Flexible Link and Variance Functions

  2005cited by this paper
• Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility.

  2005cited by this paper
• Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report.

  2005cited by this paper
• A systematic review of cost-effectiveness analyses of pharmacogenomic interventions.

  2004cited by this paper
• Azathioprine dose escalation in inflammatory bowel disease

  2004cited by this paper
• Cost‐effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease

  2004cited by this paper
• Appendicectomy and ulcerative colitis

  2003cited by this paper
• Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods

  2002cited by this paper
• TPMT in the treatment of Crohn's disease with azathioprine

  2002influential reference
• Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis.

  2002cited by this paper
• Estimating log models: to transform or not to transform?

  2001cited by this paper
• Analysis of thiopurine methyltransferase variant alleles in childhood acute lymphoblastic leukaemia

  1999cited by this paper
• The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies.

  1999cited by this paper
• Treatment of Early-Stage Breast Cancer in the Elderly

  1998cited by this paper
• Power and Sample Size Calculations for Stochastic Cost-Effectiveness Analysis

  1998cited by this paper
• A social tariff for EuroQol: results from a UK general population survey

  1995cited by this paper
• British National Formulary

  1994cited by this paper
• Multiple imputation in health-care databases: an overview and some applications.

  1991cited by this paper

• Clinical Utility and Cost‐Effectiveness of Pretreatment NUDT15 Pharmacogenetic Testing to Prevent Thiopurine‐Induced Myelosuppression: A Genotype‐First Reverse Phenotyping Cohort Study Within the UK NIHR Inflammatory Bowel Disease Bioresource

  2025influential citation
• Examination of the TPMT and NUDT15*3 Variants to Predict the Response to Thiopurines in an Italian Cohort of Patients with Inflammatory Bowel Disease

  2025cites this paper
• Poor sample size reporting quality and insufficient sample size in economic evaluations conducted alongside pragmatic trials: A cross-sectional survey.

  2024cites this paper
• Assessing the utility of measurement methods applied in economic evaluations of pharmacogenomics applications.

  2024cites this paper
• 6-Mercaptopurine-associated Sinusoidal Obstructive Syndrome During Interim Maintenance I: A Case Report

  2024cites this paper
• Time to incorporate preemptive NUDT15 testing before starting thiopurines in inflammatory bowel disease in Asia and beyond: a review

  2023cites this paper
• Preemptive TPMT Genotyping and Adherence to Genotype-Based Therapeutic Recommendations Reduces the Healthcare Cost in Patients Receiving Azathioprine or 6-Mercaptopurine for Autoimmune Diseases

  2023cites this paper
• Quantification of COVID-19 impacts on NO2 and O3: Systematic model selection and hyperparameter optimization on AI-based meteorological-normalization methods

  2023cites this paper
• An Overview on Adverse Drug Reactions (ADR) And Its Biomarkers

  2023cites this paper
• Cost Effectiveness of Pharmacogenetic Testing for Drugs with Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines: A Systematic Review

  2022cites this paper
• Economics and Precision Medicine.

  2022cites this paper
• Economic evaluation of genomic/genetic tests: a review and future directions

  2022cites this paper
• Real-World Evaluation of Universal Germline Screening for Cancer Treatment-Relevant Pharmacogenes

  2021cites this paper
• Potato (Solanum tuberosum L.) On-farm Economic Study for Phosphorus and Potassium Fertilizers in Northwestern Ethiopia

  2021cites this paper
• Cost-effectiveness analysis of genotype screening and therapeutic drug monitoring in patients with inflammatory bowel disease treated with azathioprine therapy: a Chinese healthcare perspective using real-world data

  2021cites this paper
• Pharmacogenetic testing for adverse drug reaction prevention: systematic review of economic evaluations and the appraisal of quality matters for clinical practice and implementation

  2021cites this paper
• Pharmacogenetic-guided glimepiride therapy in type-2 diabetes mellitus: a cost-effectiveness study

  2021cites this paper
• An update on the pharmacological management of autoimmune hepatitis

  2021cites this paper
• Thiopurine S-methyltransferase and Pemphigus Vulgaris:

  2020cites this paper
• Precision medicine for rheumatologists: lessons from the pharmacogenomics of azathioprine

  2020cites this paper
• Thiopurine S-methyltransferase and Pemphigus Vulgaris: A Phenotype-Genotype Study

  2020cites this paper
• Part I: Inflammatory bowel disease

  2020cites this paper
• Pharmacogenetics

  2020cites this paper
• Canadian Association of Gastroenterology Clinical Practice Guideline for the Medical Management of Pediatric Luminal Crohn's Disease.

  2019cites this paper
• Early cost-effectiveness modeling for better decisions in public research investment of personalized medicine technologies.

  2019cites this paper
• Evidence to Support Inclusion of Pharmacogenetic Biomarkers in Randomised Controlled Trials

  2019cites this paper
• Genotype-Guided Thiopurine Dosing Does not Lead to Additional Costs in Patients With Inflammatory Bowel Disease

  2019cites this paper
• Azathioprine and Mycophenolates

  2019cites this paper
• Economic Evaluation of Companion and Complementary Diagnostics

  2019cites this paper
• Accounting for Capacity Constraints in Economic Evaluations of Precision Medicine: A Systematic Review

  2019cites this paper
• Sixteen-week versus standard eight-week prednisolone therapy for childhood nephrotic syndrome: the PREDNOS RCT.

  2019cites this paper
• Modeling the Outcome of Systematic TPMT Genotyping or Phenotyping Before Azathioprine Prescription: A Cost-Effectiveness Analysis

  2019cites this paper
• Clinical Pharmacogenomics and Personalized Medicine: New Strategies to Maximize Drug Efficacy and Avoid Adverse Drug Reaction

  2018cites this paper
• Pharmacogenetics: A strategy for personalized medicine for autoimmune diseases

  2018cites this paper
• Letter: predicting azathioprine‐associated pancreatitis in IBD—phenotype or genotype? Authors' reply

  2018cites this paper
• Cost-effectiveness analyses of genetic and genomic diagnostic tests

  2018cites this paper
• Biomarkers of adverse drug reactions

  2018cites this paper
• Canadian Association of Gastroenterology Clinical Practice Guideline for the Medical Management of Pediatric Luminal Crohn’s Disease

  2018cites this paper
• Genomics-Driven Healthcare

  2018influential citation
• Microfluidic approaches for cell-based molecular diagnosis.

  2018cites this paper
• Optimization of treatment with conventional thiopurines in inflammatory bowel disease

  2018cites this paper
• The economic case for precision medicine

  2018cites this paper
• Personalized Medicine in Cancer Treatment

  2017cites this paper
• American Gastroenterological Association Institute Technical Review on the Role of Therapeutic Drug Monitoring in the Management of Inflammatory Bowel Diseases.

  2017cites this paper
• Thiopurine S-methyltransferase polymorphisms in acute lymphoblastic leukemia, inflammatory bowel disease and autoimmune disorders: influence on treatment response

  2017cites this paper
• The challenges of implementing pharmacogenomic testing in the clinic

  2017cites this paper
• Risk factors for thiopurine‐induced myelosuppression and infections in inflammatory bowel disease patients with a normal TPMT genotype

  2017influential citation
• Chapter 23 – Systemic Lupus Erythematosus

  2016cites this paper
• Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet?

  2016cites this paper
• A Systematic Review of Economic Evaluations of Pharmacogenetic Testing for Prevention of Adverse Drug Reactions

  2016influential citation
• A Model Based Cost-Effectiveness Analysis of Routine Genotyping for CYP2D6 among Older, Depressed Inpatients Starting Nortriptyline Pharmacotherapy

  2016cites this paper
• Economic Evaluations of Pharmacogenetic and Pharmacogenomic Screening Tests: A Systematic Review. Second Update of the Literature

  2016cites this paper
• An Update on Treatment and Management of Pediatric Systemic Lupus Erythematosus

  2016cites this paper
• Examining perceptions of the usefulness and usability of a mobile-based system for pharmacogenomics clinical decision support: a mixed methods study

  2016cites this paper
• Optimizing treatment with psychotropic agents through precision drug therapy

  2016cites this paper
• The Outlier in All of Us: Why Implementing Pharmacogenomics Could Matter for Everyone

  2016cites this paper
• La pharmaco-toxicogénétique et ses applications médicales

  2016cites this paper
• Enabling personalized cancer medicine decisions: The challenging pharmacological approach of PBPK models for nanomedicine and pharmacogenomics (Review).

  2016cites this paper
• Cost-Effectiveness of Pharmacogenomic and Pharmacogenetic Test-Guided Personalized Therapies: A Systematic Review of the Approved Active Substances for Personalized Medicine in Germany

  2016influential citation
• Characteristics of azathioprine use and cessation in a longitudinal lupus cohort

  2015cites this paper
• The cohabitation of art and genomic science

  2015cites this paper
• Unmet medical needs in lupus nephritis: solutions through evidence-based, personalized medicine

  2015cites this paper
• The role and advances of immunomodulator therapy for inflammatory bowel disease

  2015cites this paper
• Personalization of the Immunosuppressive Treatment in Renal Transplant Recipients: The Great Challenge in “Omics” Medicine

  2015cites this paper
• TPMT Testing Before Starting Azathioprine or Mercaptopurine: Surely Just Do It?

  2015cites this paper
• Identification of Patients With Variants in TPMT and Dose Reduction Reduces Hematologic Events During Thiopurine Treatment of Inflammatory Bowel Disease.

  2015cites this paper
• Pemphigus. S2 Guideline for diagnosis and treatment – guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV)

  2015cites this paper
• Clinical implications of neuropharmacogenetics.

  2015cites this paper
• Optimisation de la réponse aux thiopurines par la pharmacogénétique : approches in vitro et cliniques

  2014cites this paper
• Is personalized medicine achievable in obstetrics?

  2014cites this paper
• Pharmacogenetics and immunosuppressive drugs in solid organ transplantation

  2014cites this paper
• Physicians’ Knowledge and Perception of Gene Profiling in Malaysia

  2014cites this paper
• Economics of Stratified Medicine in Rheumatoid Arthritis

  2014cites this paper
• Biomarkers to assess the efficiency of treatment with platinum-based drugs: what can metallomics add?

  2014cites this paper
• Reflections on market access for personalized medicine: recommendations for Europe.

  2013cites this paper
• Pharmacogenomics and Personalized Medicine Dovepress Economic Evaluations of Personalized Medicine: Existing Challenges and Current Developments

  year unknowncites this paper